# Doxil, Bevacizumab and Temsirolimus Trial

> **NCT00761644** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 200 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Doxil
- **DRUG:** Bevacizumab
- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT00761644
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08-21
- **Primary completion:** 2019-03-28
- **Final completion:** 2019-03-28
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2019-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00761644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00761644, "Doxil, Bevacizumab and Temsirolimus Trial". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00761644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*